235 related articles for article (PubMed ID: 15265806)
1. Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation.
Nylander S; Mattsson C; Ramström S; Lindahl TL
Br J Pharmacol; 2004 Aug; 142(8):1325-31. PubMed ID: 15265806
[TBL] [Abstract][Full Text] [Related]
2. The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation.
Nylander S; Mattsson C; Ramström S; Lindahl TL
Thromb Res; 2003; 111(1-2):65-73. PubMed ID: 14644082
[TBL] [Abstract][Full Text] [Related]
3. ADP secretion and subsequent P2Y12 receptor signalling play a crucial role in thrombin-induced ERK2 activation in human platelets.
Fälker K; Lange D; Presek P
Thromb Haemost; 2004 Jul; 92(1):114-23. PubMed ID: 15213852
[TBL] [Abstract][Full Text] [Related]
4. Effects of inhibition of P2Y(1) and P2Y(12) on whole blood clotting, coagulum elasticity and fibrinolysis resistance studied with free oscillation rheometry.
Ramström S; Rånby M; Lindahl TL
Thromb Res; 2003 Mar; 109(5-6):315-22. PubMed ID: 12818256
[TBL] [Abstract][Full Text] [Related]
5. P2Y12 ADP receptor-dependent tyrosine phosphorylation of proteins of 27 and 31 kDa in thrombin-stimulated human platelets.
Fälker K; Lange D; Presek P
Thromb Haemost; 2005 May; 93(5):880-8. PubMed ID: 15886804
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
Graff J; Klinkhardt U; Harder S
Thromb Res; 2004; 113(5):295-302. PubMed ID: 15183041
[TBL] [Abstract][Full Text] [Related]
7. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity.
Leon C; Ravanat C; Freund M; Cazenave JP; Gachet C
Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1941-7. PubMed ID: 12933533
[TBL] [Abstract][Full Text] [Related]
8. Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb)beta3 activation: association with Rap1B activation.
Kamae T; Shiraga M; Kashiwagi H; Kato H; Tadokoro S; Kurata Y; Tomiyama Y; Kanakura Y
J Thromb Haemost; 2006 Jun; 4(6):1379-87. PubMed ID: 16706985
[TBL] [Abstract][Full Text] [Related]
9. Platelet collagen receptor integrin alpha2beta1 activation involves differential participation of ADP-receptor subtypes P2Y1 and P2Y12 but not intracellular calcium change.
Jung SM; Moroi M
Eur J Biochem; 2001 Jun; 268(12):3513-22. PubMed ID: 11422381
[TBL] [Abstract][Full Text] [Related]
10. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets.
Bambace NM; Levis JE; Holmes CE
Platelets; 2010; 21(2):85-93. PubMed ID: 20063989
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
12. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.
Storey RF; Sanderson HM; White AE; May JA; Cameron KE; Heptinstall S
Br J Haematol; 2000 Sep; 110(4):925-34. PubMed ID: 11054084
[TBL] [Abstract][Full Text] [Related]
13. Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets.
Jagroop IA; Burnstock G; Mikhailidis DP
Platelets; 2003 Feb; 14(1):15-20. PubMed ID: 12623443
[TBL] [Abstract][Full Text] [Related]
14. Effects on blood compatibility in vitro by combining a direct P2Y12 receptor inhibitor and heparin coating of stents.
Christensen K; Larsson R; Emanuelsson H; Elgue G; Larsson A
Platelets; 2006 Aug; 17(5):318-27. PubMed ID: 16928604
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
16. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin.
Cattaneo M; Lecchi A
J Thromb Haemost; 2007 Mar; 5(3):577-82. PubMed ID: 17155953
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of species differences in the platelet ADP and thrombin response.
Nylander S; Mattsson C; Lindahl TL
Thromb Res; 2006; 117(5):543-9. PubMed ID: 15921723
[TBL] [Abstract][Full Text] [Related]
19. Evidence that the purinergic receptor P2Y12 potentiates platelet shape change by a Rho kinase-dependent mechanism.
Hardy AR; Hill DJ; Poole AW
Platelets; 2005 Nov; 16(7):415-29. PubMed ID: 16236603
[TBL] [Abstract][Full Text] [Related]
20. Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog.
Chhatriwala M; Ravi RG; Patel RI; Boyer JL; Jacobson KA; Harden TK
J Pharmacol Exp Ther; 2004 Dec; 311(3):1038-43. PubMed ID: 15345752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
